{"id":"W4283392950","doi":"10.1097/01.hs9.0000847476.69621.cd","title":"P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacokinetics; Antibody-drug conjugate; Internal medicine; Cmax; Refractory (planetary science); Phases of clinical research; Gastroenterology; Lymphoma; Oncology; Antibody; Pharmacology; Toxicity; Adverse effect; Monoclonal antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001131587,0.0009287666,0.000969891,0.0002576225,0.0003069499,0.0008982174,0.0004795006,0.0006356331,0.001474634],"category_scores_gemma":[0.0007462715,0.0003163766,0.0006152525,0.0002773019,0.0006629403,0.00055511,0.0002369561,0.001821731,0.0005246271],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007082948,"about_ca_system_score_gemma":0.0007827262,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008074985,"about_ca_topic_score_gemma":0.001284449,"domain_scores_codex":[0.9996752,0.0001467212,0.00001795028,0.00006013649,0.00004475451,0.0000552548],"domain_scores_gemma":[0.9994943,0.00009530266,0.0001005339,0.00005295056,0.00003879366,0.0002180233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2645246,0.1211778,0.03163755,0.000864737,0.001788946,0.001589726,0.001162422,0.007560436,0.3343591,0.0003590159,0.006223222,0.2287525],"study_design_scores_gemma":[0.1215625,0.7594804,0.05660569,0.00003571452,0.001074639,0.001901004,0.0001722202,0.004787802,0.04858062,0.0002194383,0.005512042,0.00006788293],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966699,0.0007368517,0.0008077049,0.0001047659,0.00001795333,0.0004312244,0.0004417584,0.00008194449,0.0007079272],"genre_scores_gemma":[0.9954001,0.0004806635,0.0009383716,0.0002554927,0.00004885194,0.0003072839,0.001582067,0.00003428449,0.0009528016],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001474634,"threshold_uncertainty_score":0.005984485,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0126925416239034,"score_gpt":0.2900373408021528,"score_spread":0.2773447991782494,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}